Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tenofovir Alafenamide Fumarate

FDA-approved product (tablet, oral), marketed as Tenofovir Alafenamide, Tenofovir Alafenamide Fumarate, Vemlidy.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tenofovir Alafenamide Fumarate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis B virus infection
  • Hepatitis B virus infection
  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF13

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA35.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli42.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tenofovir Alafenamide Fumarate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tenofovir Alafenamide Fumarate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection

    NCT04925752 · start 2021-06-28

    Registered record
    Registry ID
    NCT04925752
    Conditions
    Pre-Exposure Prophylaxis of HIV Infection
    Interventions
    Oral Lenacapavir (LEN); F/TDF; Sub-cutaneous (SC) Lenacapavir (LEN); Placebo SC LEN; PTM F/TDF; PTM Oral LEN; F/TAF (for US participants only)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-06-28
    Completion
    2028-08
    Enrolment
    3,292

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPre-Exposure Prophylaxis of HIV Infection
    InterventionOral Lenacapavir (LEN); F/TDF; Sub-cutaneous (SC) Lenacapavir (LEN); Placebo SC LEN +3 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis B

    NCT04850950 · start 2021-04-26

    Registered record
    Registry ID
    NCT04850950
    Conditions
    Chronic Hepatitis B; Mother-to-Child Transmission; Safety; Efficacy; Hepatitis B Virus; Tenofovir Alafenamide Fumarate
    Interventions
    Tenofovir Alafenamide fumarate 25mg Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-04-26
    Completion
    2022-12-31
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B; Mother-to-Child Transmission; Safety; Efficacy +2 more
    InterventionTenofovir Alafenamide fumarate 25mg Oral Tablet
    PhasePhase 4
    Registry statusUnknown

  • Pre-Exposure Prophylaxis for Transgender Women in the US and South America

    NCT04742491 · start 2021-03-26

    Registered record
    Registry ID
    NCT04742491
    Conditions
    HIV Prevention
    Interventions
    Immediate Intervention Arm; Deferred Intervention Arm
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-03-26
    Completion
    2024-08-16
    Enrolment
    304

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Prevention
    InterventionImmediate Intervention Arm; Deferred Intervention Arm
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

    NCT04454567 · start 2020-11-11

    Registered record
    Registry ID
    NCT04454567
    Conditions
    Chronic Hepatitis B
    Interventions
    ABI-H0731; Placebo; NrtI
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-11-11
    Completion
    2021-04-08
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionABI-H0731; Placebo; NrtI
    PhasePhase 2
    Registry statusTerminated

  • Contribution of Dolutegravir to Obesity and Cardiovascular Disease

    NCT04340388 · start 2020-09-17

    Registered record
    Registry ID
    NCT04340388
    Conditions
    HIV-1-infection; Antiviral Drug Adverse Reaction; Vascular Diseases; Cardiovascular Abnormalities; Abnormality of Adipose Tissue; Body Weight Changes; Body Fat Disorder; HIV-Associated Lipodystrophy Syndrome
    Interventions
    Dolutegravir 50 MG; Antiretroviral/Anti HIV
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-09-17
    Completion
    2023-02-25
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection; Antiviral Drug Adverse Reaction; Vascular Diseases; Cardiovascular Abnormalities +4 more
    InterventionDolutegravir 50 MG; Antiretroviral/Anti HIV
    PhasePhase 4
    Registry statusCompleted

  • Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.

    NCT04231565 · start 2020-06-04

    Registered record
    Registry ID
    NCT04231565
    Conditions
    Hepatitis B Virus
    Interventions
    Tenofovir alafenamide Fumarate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2020-06-04
    Completion
    2027-07-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B Virus
    InterventionTenofovir alafenamide Fumarate
    PhaseNot applicable
    Registry statusRecruiting

  • The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants

    NCT04424264 · start 2019-12-05

    Registered record
    Registry ID
    NCT04424264
    Conditions
    HIV-1-infection; Tuberculosis
    Interventions
    Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid; Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid; Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-12-05
    Completion
    2020-10-30
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection; Tuberculosis
    InterventionPhase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid; Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid; Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz
    PhasePhase 1
    Registry statusCompleted

  • BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) Study

    NCT03916328 · start 2019-12-03

    Registered record
    Registry ID
    NCT03916328
    Conditions
    Bone Loss
    Interventions
    B/F/TAF; TDF/3TC/EFV or DTG or NVP; DMPA
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-12-03
    Completion
    2024-03-31
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone Loss
    InterventionB/F/TAF; TDF/3TC/EFV or DTG or NVP; DMPA
    PhasePhase 4
    Registry statusUnknown

  • A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

    NCT04129554 · start 2019-11-06

    Registered record
    Registry ID
    NCT04129554
    Conditions
    Hepatitis B, Chronic
    Interventions
    JNJ-73763989; JNJ-56136379; Placebo for JNJ-73763989; Placebo for JNJ-56136379; Entecavir (ETV) monohydrate; Tenofovir disoproxil fumarate (TDF); Tenofovir alafenamide (TAF)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-11-06
    Completion
    2022-06-09
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B, Chronic
    InterventionJNJ-73763989; JNJ-56136379; Placebo for JNJ-73763989; Placebo for JNJ-56136379 +3 more
    PhasePhase 2
    Registry statusCompleted

  • Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus

    NCT04059198 · start 2019-10-10

    Registered record
    Registry ID
    NCT04059198
    Conditions
    Hepatitis B; HBV; Hepatitis B, Chronic
    Interventions
    Inarigivir soproxil; Tenofovir alafenamide fumarate (TAF)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-10-10
    Completion
    2020-04-02
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B; HBV; Hepatitis B, Chronic
    InterventionInarigivir soproxil; Tenofovir alafenamide fumarate (TAF)
    PhasePhase 2
    Registry statusTerminated

  • Mesenchymal Stem Cells Treatment for Decompensated Liver Cirrhosis

    NCT03945487 · start 2019-05-20

    Registered record
    Registry ID
    NCT03945487
    Conditions
    Decompensated Liver Cirrhosis
    Interventions
    umbilical cord-derived mesenchymal stem cell; Comprehensive treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-05-20
    Completion
    2023-12-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDecompensated Liver Cirrhosis
    Interventionumbilical cord-derived mesenchymal stem cell; Comprehensive treatment
    PhasePhase 2
    Registry statusUnknown

  • Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Chronic Hepatitis b

    NCT04195074 · start 2019-01-01

    Registered record
    Registry ID
    NCT04195074
    Conditions
    Chronic Hepatitis b
    Interventions
    Entecavir; Tenofovir Disoproxil Fumarate; Tenofovir Alafenamide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-01-01
    Completion
    2024-12-31
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis b
    InterventionEntecavir; Tenofovir Disoproxil Fumarate; Tenofovir Alafenamide
    PhaseNot applicable
    Registry statusUnknown

  • Treatment Efficacy and Safety of TDF-TAF Switch Study in South Korea

    NCT03559790 · start 2018-07-18

    Registered record
    Registry ID
    NCT03559790
    Conditions
    Chronic Hepatitis b
    Interventions
    tenofovir alafenamide
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-07-18
    Completion
    2021-08
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis b
    Interventiontenofovir alafenamide
    PhaseNot recorded
    Registry statusUnknown

  • A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression

    NCT03693508 · start 2018-04-13

    Registered record
    Registry ID
    NCT03693508
    Conditions
    HIV Infections; Severe Immunosuppression
    Interventions
    Genvoya®
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-04-13
    Completion
    2020-05-28
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Severe Immunosuppression
    InterventionGenvoya®
    PhasePhase 4
    Registry statusCompleted

  • Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B

    NCT03491553 · start 2018-04-06

    Registered record
    Registry ID
    NCT03491553
    Conditions
    Chronic Hepatitis B
    Interventions
    Selgantolimod; Placebo; Hepatitis B virus (HBV) OAV Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-04-06
    Completion
    2020-08-10
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionSelgantolimod; Placebo; Hepatitis B virus (HBV) OAV Therapy
    PhasePhase 2
    Registry statusCompleted